Enlivex Therapeutics Ltd. has announced positive topline data from the Phase IIa stage of their clinical trial ENX-CL-05-001, which evaluates the efficacy of Allocetra™ in treating patients with moderate-to-severe knee osteoarthritis. The trial, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled study, demonstrated significant improvements in the treatment arm. In the modified intention-to-treat population, there was a 24% reduction in knee pain and a 26% improvement in knee function. Notably, in age-related primary osteoarthritis patients, a 72% reduction in knee pain and a 95% improvement in knee function were observed compared to placebo. The treatment also exhibited a favorable safety profile with no severe adverse events reported. The results were presented during a webinar held on August 18, 2025.